On August 18, GIANT BIOGENE fell 5.51% in regular trading, trading at HK$28.28/share, with turnover of HK$49.84 million. The decline came amid a broad selloff in Hong Kong-listed new consumer and personal care stocks.
On the news front, peer company Shanghai Jahwa (Upper Beauty) plunged over 28% after warning that its interim profit would decline 76.6%-78.4%, sparking market concerns over the earnings outlook for the beauty and skincare sector. GIANT BIOGENE was simultaneously scheduled to hold a board meeting on the same day to review its interim results for the six months ended June 30, creating a dual overhang of sector-wide sentiment pressure and its own earnings disclosure window.
For context, the company previously reported annual revenue of RMB 5.519 billion for fiscal year ended December 2025, down 0.4% year-over-year, with net profit declining 7.1%. Within the Personal Products sector, CHICMAX fell 29.2%, MAO GEPING fell 3.43%, HENGAN INT'L fell 1.48%, and BUTONG GROUP fell 1.35%, reflecting widespread sector weakness.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments